In this article, we are going to take a look at where Hikma Pharmaceuticals PLC (LON:HIK.L) stands against the other U.K.

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.35% to £19.82 Friday, on what proved to be an all-around favorable ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

Shares of Hikma Pharmaceuticals PLC HIK inched up 0.05% to £19.89 Tuesday, on what proved to be an all-around great trading ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

( MENAFN - Mid-East Info) Amman, Jordan: Hikma Pharmaceuticals PLC (Hikma, Group), the multinational Pharmaceutical group, ...

Most readers would already be aware that Hikma Pharmaceuticals' (LON:HIK) stock increased significantly by 5.3% over the past month. As most would know, fundamentals are what usually guide market ...

Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,921.22 ($24.37) and ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...